Cafer Budak

Cafer Budak

Auto-generated profile, based on publicly available information

Cafer Budak

Department of Electric-Electronic Engineering, Dicle University, Diyarbakır 21280, Türkiye

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2021 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
CBCafer Budak
Cafer Budak
VMVasfiye Mençik
Vasfiye Mençik
VGVeysel Gider
Veysel Gider
COVID-19 is a worldwide health crisis seriously endangering the arsenal of antiviral and antibiotic drugs. It is urgent to find an effective antiviral drug against pandemic caused by the severe acute respiratory syndrome (Sars-Cov-2), which increases global health concerns. As it can be expensive and time-consuming to develop specific antiviral drugs, reuse of FDA-approved drugs that provide an opportunity to rapidly distribute effective therapeutics can allow to provide treatments with known preclinical, pharmacokinetic, pharmacodynamic and toxicity profiles that can quickly enter in clinical trials. In this study, using the structural information of molecules and proteins, a list of repurposed drug candidates was prepared again with the graph neural network-based GEFA model. The data set from the public databases DrugBank and PubChem were used for analysis. Using the Tanimoto/jaccard similarity analysis, a list of similar drugs was prepared by comparing the drugs used in the treatment of COVID-19 with the drugs used in the treatment of other diseases. The resultant drugs were compared with the drugs used in lung cancer and repurposed drugs were obtained again by calculating the binding strength between a drug and a target. The kinase inhibitors (erlotinib, lapatinib, vandetanib, pazopanib, cediranib, dasatinib, linifanib and tozasertib) obtained from the study can be used as an alternative for the treatment of COVID-19, as a combination of blocking agents (gefitinib, osimertinib, fedratinib, baricitinib, imatinib, sunitinib and ponatinib) such as ABL2, ABL1, EGFR, AAK1, FLT3 and JAK1, or antiviral therapies (ribavirin, ritonavir-lopinavir and remdesivir). Communicated by Ramaswamy H. Sarma

30 April 2023 in Traitement du Signal
Verified
Journal Article
Closed access
UTUmut Tatli
Umut Tatli
CBCafer Budak
Cafer Budak

1 February 2024 in Wireless Personal Communications
Verified
Journal Article
Closed access
PDF file
CBCafer Budak
Cafer Budak
SKSecil Karatay
Secil Karatay
FEFaruk Erken
Faruk Erken
ACAli Cinar
Ali Cinar



29 March 2022 in Neural Computing and Applications
Verified
Journal Article
Closed access
PDF file
CBCafer Budak
Cafer Budak
VMVasfiye Mençik
Vasfiye Mençik